COVID-19 treatments: under evaluation

The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.

COVID-19 treatments under rolling review

EMA’s CHMP is evaluating the following COVID-19 treatments:

Treatment Treatment developer Key milestones More information
REGN-COV2 antibody combination (casirivimab / imdevimab)  Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd (Roche)
Start of rolling review: 01/02/2021
Monoclonal antibody regdanvimab Celltrion Start of rolling review: 24/02/2021 EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19
Monoclonal antibodies bamlanivimab and etesevimab Eli Lilly Start of rolling review: 11/03/2021 EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesevimab for COVID-19


How useful was this page?

Add your rating
5 ratings
1 rating
1 rating
1 rating